Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia Therapy
Data on acute myeloid leukemia therapy published by investigators at National Center for Scientific Research
March 9th, 2008
Current study results from the report, 'Disruption of the ETV6 gene as a consequence of a rare translocation (12;12)(p13;q13) in treatment-induced acute myeloid leukemia after breast cancer,' have been published. According to recent research from Athens, Greece, "We describe a case of treatment-induced acute myeloid leukemia M2 after breast cancer with a rare reciprocal t(12;12)(p13;q13) as a secondary cytogenetic abnormality in addition to the t(11;19)(q23;p13.1). Fluorescence in situ hybridization analysis revealed that both ETV6 genes (previously TEL) were located on the same der(12)t(12;12) as a result of t(12;12)." "Interestingly, the translocated ETV6 gene was...
Source: Pharma Investments, Ventures & Law Weekly (2008-03-09)
|
